Actively Recruiting
Treatment of Pediatric Post-traumatic Stress Disorder With Memory Reactivation Under the Influence of Propranolol
Led by University Hospital, Toulouse · Updated on 2023-08-28
92
Participants Needed
1
Research Sites
239 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
By age 18, roughly 8% of traumatized youth have met criteria for a diagnosis of PTSD, with numbers rising up to 40% in cases of sexual abuse and assault. To date there is no empirical support for the use of psychopharmacological interventions as treatment of pediatric PTSD. Trauma-focused psychotherapeutic/TFP approaches should be favored in childhood PTSD. However, when compared to active control conditions, TFP produced a mean effect size on child and adolescents population (g=0.83). Moreover, in therapies with a substantial exposure component, the intense and lengthy reexperiencing of the traumatic event results in a substantial proportion of participants dropping out. The reactivation of a previously consolidated memory can make it labile, subsequently requiring a re-stabilization of it called reconsolidation of the memory. Acting on these reconsolidation processes makes possible to interfere with the subsequent storage of this memory.
CONDITIONS
Official Title
Treatment of Pediatric Post-traumatic Stress Disorder With Memory Reactivation Under the Influence of Propranolol
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Children aged 7-12 years
- CPTS-RI total score 60
- Primary diagnosis of PTSD (6 months or more after the traumatic event)
- Heart rate 65 bpm
- Systolic blood pressure 95 mm Hg
- Affiliation to a social security scheme
- Written consent signed by the parents/holders of parental authority and the investigator
- Acceptance of the protocol by the child-Child and Parents/Holders of parental authority fluent in French
You will not qualify if you...
- Age under 7 years or 13 years and older
- Children whose parents have been deprived of their authority
- Contraindication to propranolol (cardiogenic shock, sinus bradycardia, hypotension, greater than first-degree heart block, heart failure, bronchial asthma, hypersensitivity to propranolol hydrochloride)
- Concurrent medication with possible interactions with propranolol
- Concurrent psychotropic drugs effective in improving PTSD symptoms (antidepressants, atypical antipsychotics, mood stabilizers)
- Concurrent psychotherapy (more than 1 structured session per month)
- Current active psychosis, anorexia nervosa, bulimia nervosa, binge-eating disorder, attention-deficit hyperactivity disorder, autism spectrum disorder
- Children with psoriasis
- Children with a predisposition to hypoglycemia
- Obsessive-compulsive disorders
- Bipolar disorders
- Mental retardation
- Traumatic brain injury (loss of consciousness more than 10 minutes)
- Currently treated with a bradycardic drug
- Concurrent participation in another interventional study
- Renal or hepatic impairment
- Pregnancy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Toulouse University Hospital
Toulouse, France, 31059
Actively Recruiting
Research Team
P
Philippe Birmes, PH
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here